Related Experiment Video

Updated: May 18, 2026

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies
07:59

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies

Published on: May 31, 2024

The TGF-β pathway as an emerging target for Chagas disease therapy

T C Araújo-Jorge1, M C Waghabi, S Bailly

  • 1Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil.

Clinical Pharmacology and Therapeutics
|September 20, 2012
PubMed

Insights

Transforming growth factor-β (TGF-β) drives Chagas disease cardiomyopathy by affecting parasite invasion, inflammation, and heart remodeling. Therapies targeting TGF-β signaling may help manage cardiac damage in patients.

Area of Science:

  • Cardiovascular Biology
  • Parasitology
  • Immunology

Background:

  • Chagas disease, caused by *Trypanosoma cruzi*, frequently leads to cardiomyopathy.
  • Transforming growth factor-β (TGF-β) plays a critical role in the pathogenesis of Chagas disease cardiomyopathy.
  • Understanding TGF-β's multifaceted influence is key to developing effective treatments.

Purpose of the Study:

  • To review the mechanisms by which TGF-β influences Chagas disease cardiomyopathy.
  • To explore the potential of TGF-β signaling-interfering therapies as an adjuvant treatment strategy.

Main Methods:

  • Literature review of studies investigating TGF-β in Chagas disease.
  • Analysis of TGF-β's role in parasite-host interactions and cardiac remodeling.
  • Evaluation of current therapeutic strategies and future directions.

Main Results:

  • TGF-β regulates parasite invasion and intracellular cycle.
  • TGF-β mediates inflammation, immune response, and cardiac fibrosis.
  • TGF-β impacts gap junction function and cardiac conduction.

Conclusions:

  • TGF-β signaling is a central mediator of cardiac pathology in Chagas disease.
  • Targeting TGF-β pathways offers a promising adjuvant therapeutic avenue for managing Chagas cardiomyopathy.

More Related Videos

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System06:13

Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System

Published on: July 31, 2019

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...